SENS-AI
LHC Trading Statement Neutral

LIFE HEALTHCARE GROUP HOLDINGS LIMITED - Trading statement for the year ended 30 September 2026

Life Healthcare Group Holdings Limited
Full analysis

What this filing means

Life Healthcare guides full-year NEPS from continuing operations to 106.3 to 111.3 cents, up 6% to 11% on a pro forma basis — a range that broadly overlaps the 6% to 10% guide it set at the May interims, while extending 1 percentage point above its upper bound. The prior-year LMI disposal distorts the reported figures, with EPS from continuing and discontinued operations guided down 63% to 68% year-on-year. The filing's own preferred measure, NEPS, shows the southern African underlying business growing broadly in line with what management had already told the market to expect.

Life Healthcare's underlying southern African business is expected to grow earnings by about 6% to 11% — broadly in line with what the company said it would do back in May, though the top of that range sits a touch above the earlier 6% to 10% guide. The confusing part is the reported numbers: last year's sale of Life Molecular Imaging created a one-off gain that makes this year's headline figures look much worse than the actual business performance. The company is telling investors to focus on the normalised number, which strips out that noise.

Bull case

  • Expected HEPS from continuing and discontinued operations is 96.0 to 100.5 cents, representing pro forma growth of 8% to 13%.
  • Expected EPS from continuing operations is 94.1 to 98.8 cents, with a pro forma change of 0% to 5%.
  • Expected NEPS from continuing operations is 106.3 to 111.3 cents, representing pro forma growth of 6% to 11%.

Bear case

  • HEPS from continuing operations is expected to decline by -1% to -6% on the pro forma basis, despite NEPS growth.
  • EPS from continuing and discontinued operations is expected to fall 63% to 68% on the reported basis, reflecting the prior-year LMI disposal gain dropping out.
  • No cash-flow or balance-sheet data is disclosed, leaving the quality of earnings and cash conversion unshown.
  • No segmental revenue or margin breakdown is provided, limiting visibility into the underlying business performance behind the earnings guidance.
  • The dividend is not addressed, leaving the full-year distribution outcome for the full results.

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

A preliminary guidance update, not a completed result. The expected NEPS growth of 6% to 11% broadly matches the 6% to 10% guide, with the upper bound extending 1 percentage point above it; final results remain outstanding. The mixed picture across EPS, HEPS and NEPS measures reflects the LMI disposal distortion rather than any change in the underlying business. So what: the underlying business is tracking as guided, but the market still needs the full results on 26 November to see cash flow, the dividend and segment detail.

The full results on 26 November are where the market will test whether the NEPS growth is backed by operating cash flow and what the dividend outcome is.

Evidence from the filing

  • HEPS from continuing operations is expected to decline by -1% to -6% on the pro forma basis, despite NEPS growth.

    “ HEPS +100.7 to 106.0 -93.9 201.0 107.1 >100% -1% to - 6%”

  • EPS from continuing and discontinued operations is expected to fall 63% to 68% on the reported basis, reflecting the prior-year LMI disposal gain dropping out.

    “ EPS +84.2 to +97.3 263.0 - 263.0 -63% to -68% -63% to -68%”

  • Expected HEPS from continuing and discontinued operations is 96.0 to 100.5 cents, representing pro forma growth of 8% to 13%.

    “ HEPS +96.0 to +100.5 -112.1 201.0 88.9 >100% +8% to +13%”

  • Expected EPS from continuing operations is 94.1 to 98.8 cents, with a pro forma change of 0% to 5%.

    “ EPS +94.1 to +98.8 -106.9 201.0 94.1 >100% 0% to 5%”

  • Expected NEPS from continuing operations is 106.3 to 111.3 cents, representing pro forma growth of 6% to 11%.

    “ NEPS +106.3 to +111.3 100.3 - 100.3 6% to 11% 6% to 11%”
Category
Trading Statement
Event posture
No Edge
Published
Nov 12, 2026

More on Life Healthcare Group Holdings Limited

Life Healthcare Group Holdings Limited (LHC) share price All Life Healthcare Group Holdings Limited SENS announcements

Related filings